Henry Schein (DE:HS2)

FRANKFURT:HS2

HS2

Henry Schein

RESEARCH TOOLSreports

Henry Schein (HS2) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HS2 Analyst Ratings

Moderate Buy

7 Buy

5 Hold

1 Sell

Based on 13 analysts giving stock ratings to

Henry

Schein

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HS2 Stock 12 Month Forecast

Average Price Target

€74.84

▲(15.14% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Henry Schein in the last 3 months. The average price target is €74.84 with a high forecast of €86.66 and a low forecast of €55.46. The average price target represents a 15.14% change from the last price of €65.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"53":"€53","70":"€70","87":"€87","61.5":"€61.5","78.5":"€78.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86.66014399999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€86.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.84285163636363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€74.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55.46249216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€55.46</span>\n  </div></div>","useHTML":true}}],"tickPositions":[53,61.5,70,78.5,87],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65,66.66616492307692,68.33232984615384,69.99849476923077,71.6646596923077,73.33082461538461,74.99698953846153,76.66315446153845,78.32931938461537,79.9954843076923,81.66164923076923,83.32781415384615,84.99397907692307,{"y":86.66014399999999,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65,65.75714243356643,66.51428486713287,67.2714273006993,68.02856973426573,68.78571216783217,69.5428546013986,70.29999703496503,71.05713946853146,71.8142819020979,72.57142433566433,73.32856676923076,74.0857092027972,{"y":74.84285163636363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65,64.26634555076923,63.53269110153846,62.79903665230769,62.06538220307692,61.33172775384615,60.59807330461538,59.86441885538461,59.130764406153844,58.397109956923074,57.663455507692305,56.929801058461535,56.196146609230766,{"y":55.46249216,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.72,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.34,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.54,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€86.66

Average Price Target€74.84

Lowest Price Target€55.46

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Bednar

Piper Sandler

€85.79→€78.86

Buy

21.32%

Upside

Reiterated

06/10/26

Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Henry Schein (HSIC)

Allen Lutz

Bank of America Securities

―

Buy

―

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), Insulet (NASDAQ: PODD) and Gilead Sciences (NASDAQ: GILD)

Glen Santangelo

Barclays

€74.53

Buy

14.66%

Upside

Assigned

05/07/26

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Henry Schein (NASDAQ: HSIC) and Exelixis (NASDAQ: EXEL)

Jeff Johnson

Robert W. Baird

€90.13→€84.06

Buy

29.32%

Upside

Reiterated

05/06/26

Henry Schein price target lowered to $97 from $104 at BairdHenry Schein price target lowered to $97 from $104 at Baird

Jonathan Block

Stifel Nicolaus

€72.79

Hold

11.99%

Upside

Reiterated

05/06/26

Stifel Nicolaus Keeps Their Hold Rating on Henry Schein (HSIC)

Kevin Caliendo

UBS

€75.39→€73.66

Hold

13.32%

Upside

Reiterated

05/06/26

Henry Schein price target lowered to $85 from $87 at UBSHenry Schein price target lowered to $85 from $87 at UBS

Michael Petusky

Barrington

€84.06

Buy

29.32%

Upside

Reiterated

05/06/26

Analysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), Alphatec Holdings (ATEC)

Steven Valiquette

Mizuho Securities

€76.26→€71.06

Hold

9.33%

Upside

Reiterated

05/06/26

Henry Schein price target lowered to $82 from $88 at MizuhoHenry Schein price target lowered to $82 from $88 at Mizuho

Erin Wright

Morgan Stanley

€52.86→€55.46

Sell

-14.67%

Downside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Elizabeth Anderson CFA

Evercore ISI

€77.99

Buy

19.99%

Upside

Reiterated

05/05/26

Evercore ISI Remains a Buy on Henry Schein (HSIC)

Brandon Vazquez

William Blair

€64.13

Hold

-1.34%

Downside

Reiterated

05/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Henry Schein (NASDAQ: HSIC), Viridian Therapeutics (NASDAQ: VRDN) and Q32 Bio (NASDAQ: QTTB)

David Larsen

BTIG

―

Hold

―

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (NASDAQ: QDEL), Climb Bio (NASDAQ: CLYM) and Henry Schein (NASDAQ: HSIC)

Daniel Grosslight

Citi

€86.66

Buy

33.32%

Upside

Initiated

04/16/26

Henry Schein initiated with a Buy at CitiHenry Schein initiated with a Buy at Citi

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€65.86→€75.39

Hold

15.99%

Upside

Reiterated

02/25/26

Wells Fargo Reaffirms Their Hold Rating on Henry Schein (HSIC)

John Stansel

J.P. Morgan

€67.59→€79.73

Buy

22.66%

Upside

Reiterated

02/25/26

Henry Schein price target raised to $92 from $78 at JPMorganHenry Schein price target raised to $92 from $78 at JPMorgan

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Bednar

Piper Sandler

€85.79→€78.86

Buy

21.32%

Upside

Reiterated

06/10/26

Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Henry Schein (HSIC)

Allen Lutz

Bank of America Securities

―

Buy

―

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), Insulet (NASDAQ: PODD) and Gilead Sciences (NASDAQ: GILD)

Glen Santangelo

Barclays

€74.53

Buy

14.66%

Upside

Assigned

05/07/26

Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Henry Schein (NASDAQ: HSIC) and Exelixis (NASDAQ: EXEL)

Jeff Johnson

Robert W. Baird

€90.13→€84.06

Buy

29.32%

Upside

Reiterated

05/06/26

Henry Schein price target lowered to $97 from $104 at BairdHenry Schein price target lowered to $97 from $104 at Baird

Jonathan Block

Stifel Nicolaus

€72.79

Hold

11.99%

Upside

Reiterated

05/06/26

Stifel Nicolaus Keeps Their Hold Rating on Henry Schein (HSIC)

Kevin Caliendo

UBS

€75.39→€73.66

Hold

13.32%

Upside

Reiterated

05/06/26

Henry Schein price target lowered to $85 from $87 at UBSHenry Schein price target lowered to $85 from $87 at UBS

Michael Petusky

Barrington

€84.06

Buy

29.32%

Upside

Reiterated

05/06/26

Analysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), Alphatec Holdings (ATEC)

Steven Valiquette

Mizuho Securities

€76.26→€71.06

Hold

9.33%

Upside

Reiterated

05/06/26

Henry Schein price target lowered to $82 from $88 at MizuhoHenry Schein price target lowered to $82 from $88 at Mizuho

Erin Wright

Morgan Stanley

€52.86→€55.46

Sell

-14.67%

Downside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Elizabeth Anderson CFA

Evercore ISI

€77.99

Buy

19.99%

Upside

Reiterated

05/05/26

Evercore ISI Remains a Buy on Henry Schein (HSIC)

Brandon Vazquez

William Blair

€64.13

Hold

-1.34%

Downside

Reiterated

05/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Henry Schein (NASDAQ: HSIC), Viridian Therapeutics (NASDAQ: VRDN) and Q32 Bio (NASDAQ: QTTB)

David Larsen

BTIG

―

Hold

―

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (NASDAQ: QDEL), Climb Bio (NASDAQ: CLYM) and Henry Schein (NASDAQ: HSIC)

Daniel Grosslight

Citi

€86.66

Buy

33.32%

Upside

Initiated

04/16/26

Henry Schein initiated with a Buy at CitiHenry Schein initiated with a Buy at Citi

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€65.86→€75.39

Hold

15.99%

Upside

Reiterated

02/25/26

Wells Fargo Reaffirms Their Hold Rating on Henry Schein (HSIC)

John Stansel

J.P. Morgan

€67.59→€79.73

Buy

22.66%

Upside

Reiterated

02/25/26

Henry Schein price target raised to $92 from $78 at JPMorganHenry Schein price target raised to $92 from $78 at JPMorgan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Henry Schein

3 Months

Michael PetuskyBarrington

Success Rate

21/37 ratings generated profit

Average Return

+2.26%

Copying Michael Petusky's trades and holding each position for 3 Months would result in 56.76% of your transactions generating a profit, with an average return of +2.26% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

11/16 ratings generated profit

Average Return

+6.14%

Copying Allen Lutz's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +6.14% per trade.

2 Years

Allen LutzBank of America Securities

Success Rate

11/16 ratings generated profit

Average Return

+7.09%

Copying Allen Lutz's trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +7.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HS2 Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HS2 has received 9 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. HS2 average Analyst price target in the past 3 months is 74.84.

Each month's total comprises the sum of three months' worth of ratings.

HS2 Financial Forecast

HS2 Earnings Forecast

Next quarter’s earnings estimate for HS2 is €1.07 with a range of €1.01 to €1.19. The previous quarter’s EPS was €1.14. HS2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.

HS2 Sales Forecast

Next quarter’s sales forecast for HS2 is €2.93B with a range of €2.90B to €2.95B. The previous quarter’s sales results were €2.92B. HS2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.

HS2 Stock Forecast FAQ

What is DE:HS2’s average 12-month price target, according to analysts?

Based on analyst ratings, Henry Schein’s 12-month average price target is 74.84.

What is DE:HS2’s upside potential, based on the analysts’ average price target?

Henry Schein has 15.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Henry Schein a Buy, Sell or Hold?

Henry Schein has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 5 hold ratings and 1 sell ratings.

What is Henry Schein’s share price target?

The average share price target for Henry Schein is 74.84. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €86.66 ,and the lowest forecast is €55.46. The average share price target represents 15.14% Increase from the current price of €65.

What do analysts say about Henry Schein?

Henry Schein’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Henry Schein?

To buy shares of DE:HS2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Henry Schein (HS2) Stock Forecast & Price Target

HS2 Analyst Ratings

HS2 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Henry Schein

HS2 Analyst Recommendation Trends

HS2 Financial Forecast

HS2 Earnings Forecast

HS2 Sales Forecast

HS2 Stock Forecast FAQ

Detailed List of Analyst Forecasts